HBM Holdings Limited

Direct answer

HBM Holdings Limited is publicly traded on HKSE under the ticker 2142.HK.

HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while...

Can you invest in HBM Holdings Limited?

Yes. HBM Holdings Limited is publicly traded on HKSE under the ticker 2142.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for HBM Holdings Limited

Detailed equity research is provided by MarketSnap.